Genetic Test for Prostate Cancer
Prostate cancer (PCa) is one of the leading causes of cancer deaths in men worldwide. Current diagnostic methods are based on the determination of the PSA tumour marker and digital rectal examination as indicators for prostate biopsy. This methodology leads to 75% of unnecessary biopsies, with costs and inconvenience for the patient.
Which patients is it most useful for?
Uses of the test:
- In the event of elevated PSA levels or clinical suspicion.
- Positive family history for prostate cancer.
- High clinical suspicion in the light of a negative biopsy.
- To determine the aggressiveness of the tumour after a positive biopsy.
- As a method of monitoring after a diagnosis of prostate cancer.
- Turnaround time: 14 working days (Monday to Friday)
At Echevarne Laboratory we offer the first genetic test to diagnose prostate cancer from a urine sample.
What does it analyse?
PCA3 is the first specific gene in the prostate capable of showing significant overexpression in tumour cells.